Allergan is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets. The company offers Alphagan, Alphagan P, Lumigan, and Restasis products for the treatment of glaucoma, and Acular, Elestat, and Alocril for the temporary relief of itch and for postoperative inflammation. It also offers Acular PF for the reduction of ocular pain and photophobia. It provides Acular LS for the reduction of ocular pain, burning and stinging, Ocuflox, an anti-infective ophthalmic solutions, and Zymar for bacterial conjunctivitis. Allergan s neuromodulator products include Botox that is used for neuromuscular disorders. The firm s skin care products include Tazorac gel for plaque psoriasis and acne, Avage for facial fine wrinkling, Azelex for mild to moderate inflammatory acne vulgaris, M.D. Forte, a glycolic acid-based skin care products, and Finacea for the treatment of rosacea. David E. I. Pyott has been the chief executive officer of Allergan for more than eight years. He has been with the drugs and bio-tech company for over eight years. Pyott earned a BS degree from the University of Edinburgh, and a MS degree from London University College. Allergan has global marketing and sales capabilities in more than 100 countries, and is located in Irvine, Calif.